Visgenx shares positive data from VGX-0111 gene therapy study in non-human primates
The study demonstrated a meaningful increase in the long chain and very long chain polyunsaturated fatty acids whose deficit is associated with dry AMD.
The study demonstrated a meaningful increase in the long chain and very long chain polyunsaturated fatty acids whose deficit is associated with dry AMD. (Image Credit: Radomir Jovanovic/Adobe Stock)
Visgenx, Inc. announced positive data from a non-human primate study of VGX-0111 to deliver the ELOVL2 transgene. The study used a single subretinal injection with the goal of investigating whether VGX-0111 expresses in the target tissues and causes an increase in very long chain polyunsaturated fatty acids at a dose that is well tolerated. VGX-0111 was able to successfully demonstrate these parameters.
While the underlying cause of dry AMD remains unknown, recent studies point to a decline in the biosynthesis of certain long chain and very long chain polyunsaturated fatty acids (LC and VLC PUFA) plays an important underlying role. The ELOVL2 enzyme plays a central role in the biosynthesis of LC and VLC PUFAs. During aging, expression of the ELOVL2 gene declines leading to a reduction in the LC and VLC PUFAs necessary for vision. VGX-0111 is an experimental gene therapy intended to increase expression of ELOVL2. It is thought that restoring physiological ELOVL2 expression will increase levels of LC and VLC PUFAs in the retina and slow or halt the progression of dry AMD.
Studies in natural aging models of dry AMD in rodents have demonstrated that a single treatment with VGX-0111 increased ELOVL2 expression and protected against photoreceptor loss. The recently completed study investigated VGX-0111 in non-human primates as the next step toward human clinical trials. The studies showed VGX -0111 was well tolerated and expressed appropriately in the targeted areas of the retina. Most importantly, the study demonstrated a meaningful increase in the LC and VLC PUFAs whose deficit is associated with dry AMD.
Martin Emanuele, PhD, Chief Science Officer of Visgenx shared his insights on this AMD theory and the outcome of this study in the news release, saying, "A robust body of scientific literature supports that long chain and very long chain polyunsaturated fatty acids play essential roles in both the vision transduction process and supporting the bioenergetics of retinal function. The findings demonstrate that it is possible to increase the fatty acids whose decline is associated with dry AMD with a well-tolerated treatment in a species closely related to humans. This is very encouraging and bodes well for further development."
